This morning in Amsterdam brought some interesting breast and ovarian cancer presentations that I thought deserved a quick recap.

One is potentially practice changing in HER2 breast cancer and the other is a new product in development (Biomarin’s BMN 673) that is worth watching out for:

To learn more top line insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.